Abstract:BackgroundIncreasing evidence has suggested that inflammation is related to tumorigenesis and tumor progression. However, the roles of immune-related genes in the occurrence, development, and prognosis of glioblastoma multiforme (GBM) remain to be studied.MethodsThe GBM-related RNA sequencing (RNA-seq), survival, and clinical data were acquired from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) databases. Immune-related genes were obtained from the Molecular Signatures Database (MSigDB). Differently expressed immune-related genes (DE-IRGs) between GBM and normal samples were identified. Prognostic genes associated with GBM were selected by Kaplan–Meier survival analysis, Least Absolute Shrinkage and Selection Operator (LASSO)-penalized Cox regression analysis, and multivariate Cox analysis. An immune-related gene signature was developed and validated in TCGA and CGGA databases separately. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to explore biological functions of the signature. The correlation between immune cell infiltration and the signature was analyzed by single-sample gene set enrichment analysis (ssGSEA), and the diagnostic value was investigated. The gene set enrichment analysis (GSEA) was performed to explore the potential function of the signature genes in GBM, and the protein–protein interaction (PPI) network was constructed.ResultsThree DE-IRGs [Pentraxin 3 (PTX3), TNFSF9, and bone morphogenetic protein 2 (BMP2)] were used to construct an immune-related gene signature. Receiver operating characteristic (ROC) curves and Cox analyses confirmed that the 3-gene-based prognostic signature was a good independent prognostic factor for GBM patients. We found that the signature was mainly involved in immune-related biological processes and pathways, and multiple immune cells were disordered between the high- and low-risk groups. GSEA suggested that PTX3 and TNFSF9 were mainly correlated with interleukin (IL)-17 signaling pathway, nuclear factor kappa B (NF-κB) signaling pathway, tumor necrosis factor (TNF) signaling pathway, and Toll-like receptor signaling pathway, and the PPI network indicated that they could interact directly or indirectly with inflammatory pathway proteins. Quantitative real-time PCR (qRT-PCR) indicated that the three genes were significantly different between target tissues.ConclusionThe signature with three immune-related genes might be an independent prognostic factor for GBM patients and could be associated with the immune cell infiltration of GBM patients.

The Immune-Related Microrna Mir-146B is Upregulated in Glioblastoma Recurrence.

Comprehensive Analysis of Multi-Omics Data of Recurrent Gliomas Identifies a Recurrence-Related Signature As a Novel Prognostic Marker.

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Tmic-84. Molecular Evolution Of The Tumor And Its Microenvironment At Recurrence

Construction of an Immune-Related Gene Signature for the Prognosis and Diagnosis of Glioblastoma Multiforme.

An Integrated Mrna and Microrna Expression Signature for Glioblastoma Multiforme Prognosis.

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Differential expression of microRNAs in postoperative radiotherapy sensitive and resistant patients with glioblastoma multiforme

Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma

Upregulation of Mir-96 Promotes Radioresistance in Glioblastoma Cells Via Targeting PDCD4

Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy

Identification of Dysregulated microRNAs in Glioblastoma Stem-Like Cells

Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma.

Microrna-1224-5p Is a Potential Prognostic and Therapeutic Biomarker in Glioblastoma: Integrating Bioinformatics and Clinical Analyses

MicroRNA Signatures Predict Prognosis of Patients with Glioblastoma Multiforme Through the Cancer Genome Atlas.

MicroRNA Expression Signatures and Their Correlation with Clinicopathological Features in Glioblastoma Multiforme

In Silico Analysis Identified Mirna-Based Therapeutic Agents Against Glioblastoma Multiforme

The Mir-92B Functions As a Potential Oncogene by Targeting on Smad3 in Glioblastomas

Fc gamma receptor IIb in tumor-associated macrophages and dendritic cells drives poor prognosis of recurrent glioblastoma through immune-associated signaling pathways

Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism

Global and Targeted Mirna Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links Mir-155-5p and Mir-210-3p to Both Tumorigenesis and Recurrence.